Displaying 1 - 9 of 9
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View